Phthalimide conjugation as a strategy for in vivo target protein degradation

Cited by (1,004)

Items 401–500 of 1,004

1. Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
   Xiaopeng Peng, Zhihao Hu, Limei Zeng, Meizhu Zhang, Congcong Xu, Benyan Lu, Chengpeng Tao, Wei‐Ming Chen, Wen Hou, Kui Cheng et al. · 2023 · Acta Pharmaceutica Sinica B
2. Concepts to Target MYC in Pancreatic Cancer
   Matthias Wirth, Siavosh Mahboobi, Oliver Holger Krämer, Günter Schneider · 2016 · Molecular Cancer Therapeutics
3. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras
   Yingming Wang, Lingfei Han, Fulei Liu, Fubai Yang, Xueyang Jiang, Haopeng Sun, Feng Feng, Jingwei Xue, Wenyuan Liu · 2020 · Colloids and Surfaces B Biointerfaces
4. Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
   Gabriel LaPlante, Wei Zhang · 2021 · Cancers
5. Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions
   Anthony Chan, Chun-Wei David Chen · 2019 · Frontiers in Cell and Developmental Biology
6. Targeting chromatin complexes in fusion protein-driven malignancies
   Gerard L. Brien, K. Stegmaier, S. Armstrong · 2019 · Nature Reviews. Cancer
7. Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction
   Xing Qiu, Ning Sun, Ying Kong, Yan Li, Xiaobao Yang, Biao Jiang · 2019 · Organic Letters
8. Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras
   Thang Do Cong, Jun Wei Lau, Caixia Sun, Songhan Liu, Tuan‐Khoa Kha, Seok Ting Lim, Yu Yang Oon, Yuet Ping Kwan, Jiajia Ma, Yuguang Mu et al. · 2022 · Science Advances
9. Development of folate receptor targeting chimeras for cancer selective degradation of extracellular proteins
   Yaxian Zhou, Chunrong Li, Xuankun Chen, Yuan Zhao, Yaxian Liao, Penghsuan Huang, Wenxin Wu, Nicholas S. Nieto, Lingjun Li, Weiping Tang · 2024 · Nature Communications
10. Mechanism of degrader-targeted protein ubiquitinability
    Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, Conner Craigon, Gajanan J. Sathe, Michael H. Tatham, Nikolai Makukhin, Ronald T. Hay, Alessio Ciulli · 2024 · Science Advances
11. Salt-Inducible Kinase inhibition suppresses acute myeloid leukemia progression in vivo.
    Y. Tarumoto, Shan Lin, Jin-Hua Wang, Joseph P Milazzo, Ya-Li Xu, Bin Lu, Zhaolin Yang, Yi-Liang Wei, Sofya A. Polyanskaya, M. Wunderlich et al. · 2019 · Blood
12. Proteome-scale discovery of protein degradation and stabilization effectors
    Juline Poirson, Hanna Cho, Akashdeep Dhillon, Shahan Haider, Ahmad Zoheyr Imrit, Mandy Hiu Yi Lam, Nader Alerasool, Jessica Lacoste, Lamisa Mizan, Cassandra J. Wong et al. · 2024 · Nature
13. UBE2G1 governs the destruction of cereblon neomorphic substrates
    Lu, Gang, Weng, Stephanie, Matyskiela, Mary, Zheng, Xinde, Fang, Wei, Wood, Scott, Surka, Christine, Mizukoshi, Reina, Lu, Chin-Chun, Mendy, Derek et al. · 2018 · eLife
14. PIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
    Reichermeier, Kurt M., Straube, Ronny, Reitsma, Justin M., Sweredoski, Michael J., Rose, Christopher M., Moradian, Annie, den Besten, Willem, Hinkle, Trent, Verschueren, Erik, Petzold, Georg et al. · 2020 · Molecular Cell
15. The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia
    Hubo Li, Brenton G. Mar, Huadi Zhang, Rishi V. Puram, Francisca Vazquez, Barbara A. Weir, William C. Hahn, Benjamin L. Ebert, David S. Pellman · 2016 · Blood
16. Multiple Myeloma Therapy: Emerging Trends and Challenges
    Danai Dima, Dongxu Jiang, Divya Jyoti Singh, Metis Hasipek, Haikoo Shah, Fauzia Ullah, Jack Khouri, Jaroslaw Pawel Maciejewski, Babal Kant Jha · 2022 · Cancers
17. Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure–Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1
    Joshua D. Hansen, Kevin R. Condroski, Matthew Correa, George W. Muller, Hon‐Wah Man, Alexander L. Ruchelman, Weihong Zhang, Fan Vocanson, Tim Crea, Wei Liu et al. · 2017 · Journal of Medicinal Chemistry
18. Development of selective small molecule MDM2 degraders based on nutlin
    Wang, Bo, Wu, Suzhen, Liu, Jin, Yang, Ka, Xie, Haibo, Tang, Weiping · 2019 · European Journal of Medicinal Chemistry
19. Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors
    Shuai Wang, Li-Jie Zhao, Yi‐Chao Zheng, Dandan Shen, Er-Fei Miao, Xue-Peng Qiao, Lijuan Zhao, Ying Min Liu, Ruilei Huang, Bin Yu et al. · 2016 · European Journal of Medicinal Chemistry
20. Molecular mechanisms of cereblon-based drugs
    Tomoko Asatsuma‐Okumura, Takumi Ito, Hiroshi Handa · 2019 · Pharmacology & Therapeutics
21. A Chemical Biology View of Bioactive Small Molecules and a Binder‐Based Approach to Connect Biology to Precision Medicines
    Stuart L. Schreiber · 2018 · Israel Journal of Chemistry
22. The Ubiquitin System in Alzheimer’s Disease
    Lee D. Harris, Sarah Jasem, Julien D. F. Licchesi · 2020 · Advances in experimental medicine and biology
23. Optimization of a Series of RIPK2 PROTACs
    Afjal H. Miah, Ian E. Smith, M.D. Rackham, Alina Mares, Aditya Raymond Thawani, Rakesh Nagilla, Pamela A. Haile, Bartholomew J. Votta, Laurie J. Gordon, Gillian F. Watt et al. · 2021 · Journal of Medicinal Chemistry
24. Recent Advances in PROTACs for Drug Targeted Protein Research
    Tingting Yao, Heng Xiao, Hong Wang, Xiaowei Xu · 2022 · International Journal of Molecular Sciences
25. Phenyl Dihydrouracil: An Alternative Cereblon Binder for PROTAC Design
    Jamie Jarusiewicz, Satoshi Yoshimura, Anand Mayasundari, Marisa Actis, Anup Aggarwal, Kevin M. McGowan, Lei Yang, Yong Li, Xiang Fu, Vibhor Mishra et al. · 2023 · ACS Medicinal Chemistry Letters
26. Advancing targeted protein degradation for metabolic diseases therapy
    Qianqian Zhou, Haitao Xiao, Fan Yang, Yongdan Wang, Ping Li, Zu‐Guo Zheng · 2022 · Pharmacological Research
27. Targeting epigenetic regulations in cancer
    Bo Ning, Wenyuan Li, Wei Zhao, Rong‐Fu Wang · 2015 · Acta Biochimica et Biophysica Sinica
28. A patent review of the ubiquitin ligase system: 2015–2018
    Xin Li, Elmira Ekinci, Sagar O. Rohondia, Jicang Wang, Jinbao Liu, Q. Ping Dou · 2018 · Expert Opinion on Therapeutic Patents
29. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
    Xuewei Wu, Xiaobao Yang, Yan Xiong, Ruitong Li, Takahiro Ito, Tamer A. Ahmed, Zoi Karoulia, Christos Adamopoulos, Hong Wang, Li Wang et al. · 2021 · Nature Cancer
30. Relocalizing transcriptional kinases to activate apoptosis
    Roman C. Sarott, Sai P. Gourisankar, Basel A. Karim, Sabin A. Nettles, Haopeng Yang, Brendan G. Dwyer, Juste Simanauskaite, Jason Tse, Hind Z. Abuzaid, A. Krokhotin et al. · 2024 · Science
31. Molecular Principles of Gene Fusion Mediated Rewiring of Protein Interaction Networks in Cancer
    Natasha S. Latysheva, Matt E. Oates, Louis Maddox, Tilman Flock, Julian Gough, Marija Buljan, Robert J. Weatheritt, M. Madan Babu · 2016 · Molecular Cell
32. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability
    Brenton R. Paolella, William J. Gibson, Laura M. Urbanski, John A. Alberta, Travis Ian Zack, Pratiti Bandopadhayay, Caitlin A. Nichols, Pankaj Kumar Agarwalla, Meredith S. Brown, Rebecca C. Lamothe et al. · 2017 · eLife
33. Optical control of targeted protein degradation
    Martin Reynders, Dirk H. Trauner · 2021 · Cell chemical biology
34. Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation
    Bin Zheng, Sarah R. Gold, Marta Iwanaszko, Benjamin Charles Howard, Lu Wang, Ali Shilatifard · 2023 · Molecular Cell
35. Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer
    Weiguo Xiang, Lijie Zhao, Xin Han, Tianfeng Xu, Steven Kregel, Mi Wang, Bukeyan Miao, Chong Qin, Mingliang Wang, Donna McEachern et al. · 2023 · Journal of Medicinal Chemistry
36. Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs
    Rebecca Stevens, Enrique Bendito-Moll, David J. Battersby, Afjal H. Miah, Natalie Wellaway, Robert P. Law, Peter Stacey, Diana Klimaszewska, Justyna M. Macina, Glenn A. Burley et al. · 2023 · Journal of Medicinal Chemistry
37. BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
    Sujan Piya, Hong Hua Mu, Seemana Bhattacharya, Philip L. Lorenzi, Richard Eric Davis, Teresa J. McQueen, Vivian R. Ruvolo, Natalia Baran, Zhiqiang Wang, Yimin Qian et al. · 2019 · Journal of Clinical Investigation
38. De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives
    Christopher Heim, Dimanthi Pliatsika, Farnoush Mousavizadeh, Kerstin Bär, Birte Hernandez Alvarez, Athanassios Giannis, Marcus D. Hartmann · 2019 · Journal of Medicinal Chemistry
39. Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated with reduced neuroinflammation and oxidative stress and preservation of blood–brain barrier integrity
    Lei Liu, Changjun Yang, Bianca P. Lavayen, Ryland J. Tishko, Jonathan Larochelle, Eduardo Candelario‐Jalil · 2022 · Journal of Neuroinflammation
40. Bromodomain inhibitors and therapeutic applications
    Bharath Kumar Gajjela, Ming‐Ming Zhou · 2023 · Current Opinion in Chemical Biology
41. Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders
    Xingui Liu, Xuan Zhang, Dongwen Lv, Yaxia Yuan, Guangrong Zheng, Daohong Zhou · 2020 · Future Medicinal Chemistry
42. Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations
    Gillian F. Watt, Paul Scott‐Stevens, Lu Gaohua · 2019 · Drug Discovery Today Technologies
43. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery
    Dailin Liang, Yifan Yu, Zonghui Ma · 2020 · European Journal of Medicinal Chemistry
44. A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands
    Bomie Han · 2020 · Journal of Biological Chemistry
45. Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos
    Fanye Meng, Chenxi Xu, Kwang‐Su Park, H. Ümit Kanıskan, Gang Greg Wang, Jian Jun Jin · 2022 · Journal of Medicinal Chemistry
46. RNA-binding protein 39: a promising therapeutic target for cancer
    Caipeng Xu, Xiaohua Chen, Xuetian Zhang, Dapeng Zhao, Zhihui Dou, Xiaodong Xie, Hongyan Li, Hongying Yang, Qiang Li, Hong Zhang et al. · 2021 · Cell Death Discovery
47. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer
    Dan Wei, Hanlin Wang, Qinghe Zeng, Wenjing Wang, Bingbing Hao, Xule Feng, Peipei Wang, Ning Song, Weijuan Kan, Guifang Huang et al. · 2021 · Journal of Medicinal Chemistry
48. Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands
    Aleša Bricelj, Yuen Lam Dora Ng, Dominic Ferber, Robert D. Kuchta, Sina Müller, Marius Monschke, Karl Gerhard Wagner, Jan Krönke, Izidor Sosič, Michael Gütschow et al. · 2021 · ACS Medicinal Chemistry Letters
49. BRD4 in physiology and pathology: ‘‘BET’’ on its partners
    Yin Liang, Jieyi Tian, Tao Wu · 2021 · BioEssays
50. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
    Yan Yi, Shenglei Ge · 2022 · Journal of Hematology & Oncology
51. Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine
    Sijun Pan, Aixiang Ding, Yisi Li, Yaxin Sun, Yueqin Zhan, Zhenkun Ye, Ning Song, Bo Peng, Lin Li, Wei Huang et al. · 2023 · Chemical Society Reviews
52. BET Bromodomain as a Target of Epigenetic Therapy
    Tomomi Noguchi‐Yachide · 2016 · Chemical and Pharmaceutical Bulletin
53. Novel approaches for the rational design of PROTAC linkers
    Almaz Anvarovich Zagidullin, Vasili A Milyukov, Albert Anatolyevich Rizvanov, Emil Bulatov · 2020 · Exploration of Targeted Anti-tumor Therapy
54. Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques
    Siyu Chen, Jingliang Cui, Haiyan Chen, Bo Yu, Sihui Long · 2023 · European Journal of Medicinal Chemistry
55. Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality
    Philip P. Chamberlain, Laura Akullian D’Agostino, J. Michael Ellis, Joshua D. Hansen, Mary E. Matyskiela, Joseph J. McDonald, Jennifer R. Riggs, Lawrence G. Hamann · 2019 · ACS Medicinal Chemistry Letters
56. Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
    Yamanaka, Satoshi, Furihata, Hirotake, Yanagihara, Yuta, Taya, Akihito, Nagasaka, Takato, Usui, Mai, Nagaoka, Koya, Shoya, Yuki, Nishino, Kohei, Yoshida, Shuhei et al. · 2023 · Nature Communications
57. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
    Thomas L. Gonzalez, Molly Hancock, Siqi Sun, Christina L. Gersch, Jose Maciel Larios, Wadie S. David, Jiantao Hu, Daniel F. Hayes, Shaomeng Wang, James Michael Rae · 2020 · Breast Cancer Research and Treatment
58. Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
    Adam J. Wolpaw, Richard W. Bayliss, Gabriele Büchel, Chi Van Dang, Martin Eilers, William Clay Gustafson, Gwenn M. Hansen, Natalia Jura, Stefan Knapp, Mark A. Lemmon et al. · 2021 · Cancer Research
59. Opportunities and challenges of protein-based targeted protein degradation
    Fangfang Shen, Laura M. K. Dassama · 2023 · Chemical Science
60. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity
    Lin Yang, Wenbin Tu, Liyue Huang, Bukeyan Miao, Atsunori Kaneshige, Wei Jiang, Lingying Leng, Meilin Wang, Bo Wen, Duxin Sun et al. · 2023 · Journal of Medicinal Chemistry
61. ClickRNA-PROTAC for Tumor-Selective Protein Degradation and Targeted Cancer Therapy
    Xucong Teng, Xuan Zhao, Yicong Dai, Xiangdong Zhang, Qiushuang Zhang, Yuncong Wu, Difei Hu, Jinghong Li · 2024 · Journal of the American Chemical Society
62. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis
    Ji Cheng, Jianping Guo, Brian J. North, Kaixiong Tao, Pengbo Zhou, Wenyi Wei · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
63. A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
    Ingeborg Menzl, Tinghu Zhang, Angelika Berger‐Becvar, Reinhard Grausenburger, Gerwin Heller, Michaela Prchal‐Murphy, Leo Edlinger, Vanessa Maria Knab, Iris Z. Uras, Eva Grundschober et al. · 2019 · Nature Communications
64. Amino acid homorepeats in proteins
    Sreenivas Chavali, Anjali Kumari Singh, Balaji Santhanam, M. Madan Babu · 2020 · Nature Reviews Chemistry
65. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
    Klaus Podar, Xavier P Leleu · 2021 · Cancers
66. The Fra-1/AP-1 Oncoprotein: From the “Undruggable” Transcription Factor to Therapeutic Targeting
    Laura Casalino, Francesco Talotta, Amelia Cimmino, Pasquale Verde · 2022 · Cancers
67. PROTACs: A novel strategy for cancer drug discovery and development
    Xin Han, Yi Sun · 2023 · MedComm
68. Induced protein degradation for therapeutics: past, present, and future
    Hojong Yoon, Justine C. Rutter, Yen-Der Li, Benjamin L. Ebert · 2024 · Journal of Clinical Investigation
69. Degradation of HaloTag-fused nuclear proteins using bestatin-HaloTag ligand hybrid molecules
    Shusuke Tomoshige, Mikihiko Naito, Yuichi Hashimoto, Minoru Ishikawa · 2015 · Organic & Biomolecular Chemistry
70. Monitoring and deciphering protein degradation pathways inside cells
    Danette L. Daniels, Kristin M. Riching, Marjeta Urh · 2018 · Drug Discovery Today Technologies
71. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
    Christoph Otto, Stefanie Schmidt, C. Kastner, Sarah Denk, J. Kettler, N. Müller, Christoph‐Thomas Germer, Elmar Wolf, Peter Gallant, Armin Wiegering · 2019 · Neoplasia
72. Targeting BET bromodomain proteins in cancer: The example of lymphomas
    Filippo Spriano, Anastasios Stathis, Francesco Bertoni · 2020 · Pharmacology & Therapeutics
73. PROTACs suppression of GSK-3β, a crucial kinase in neurodegenerative diseases
    Xueyang Jiang, Junting Zhou, Yang Wang, Xin Liu, Kaiying Xu, Jian Xu, Feng Feng, Haopeng Sun · 2020 · European Journal of Medicinal Chemistry
74. PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspective
    Xin Han, Wenyi Wei, Yi Sun · 2022 · Acta Materia Medica
75. A Versatile and Sustainable Multicomponent Platform for the Synthesis of Protein Degraders: Proof-of-Concept Application to BRD4-Degrading PROTACs
    Irene Preet Bhela, Alice Ranza, Federica Carolina Balestrero, M. Teresa Serafini, Silvio Aprile, Rita Maria Concetta Di Martino, Fabrizio Condorelli, Tracey Pirali · 2022 · Journal of Medicinal Chemistry
76. Targeting androgen receptor degradation with PROTACs from bench to bedside
    Xiaojuan Jia, Xin Han · 2022 · Biomedicine & Pharmacotherapy
77. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation
    Haibo Xie, Chunrong Li, Hua Tang, Ira Tandon, Junzhuo Liao, Brett L. Roberts, Yu Qing Zhao, Weiping Tang · 2023 · Journal of Medicinal Chemistry
78. Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
    Yu-Ling Tseng, Po-Chao Lu, Chi-Chang Lee, Ruei‐Yu He, Yung‐An Huang, Yin‐Chen Tseng, Ting-Jen Rachel Cheng, Joseph Jen‐Tse Huang, Jim‐Min Fang · 2023 · Journal of Biomedical Science
79. The rise of degrader drugs
    Mingxing Teng, Nathanael S. Gray · 2023 · Cell chemical biology
80. FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor
    Leili Ran, Yuedan Chen, Jessica J. Sher, Elissa W.P. Wong, Devan A. Murphy, Jenny Q. Zhang, Dan Li, Kemal Denız, Inna Sirota, Zhen Cao et al. · 2017 · Cancer Discovery
81. Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia
    DeMars, Kelly M., Yang, Changjun, Castro-Rivera, Carolina I., Candelario-Jalil, Eduardo · 2018 · Biochemical and Biophysical Research Communications
82. Native Mass Spectrometry Can Effectively Predict PROTAC Efficacy
    Rebecca Beveridge, Dirk Kessler, Klaus Rumpel, Peter Ettmayer, Anton Meinhart, Tim Clausen · 2020 · ACS Central Science
83. Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy
    Yunhua Peng, Jing Liu, Hiroyuki Inuzuka, Wenyi Wei · 2023 · Journal of Biological Chemistry
84. Targeted protein degradation in cancers: Orthodox PROTACs and beyond
    Jin Li, Xinxin Chen, Aiping Lü, Chao Liang · 2023 · The Innovation
85. Proteolysis-Targeting Chimeras: Harnessing the Ubiquitin-Proteasome System to Induce Degradation of Specific Target Proteins
    Kevin G. Coleman, Craig M. Crews · 2017 · Annual Review of Cancer Biology
86. Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
    Wang, Bo, Liu, Jin, Tandon, Ira, Wu, Suzhen, Teng, Peng, Liao, Jianhua, Tang, Weiping · 2021 · European Journal of Medicinal Chemistry
87. Intelligent Modular DNA Lysosome-Targeting Chimera Nanodevice for Precision Tumor Therapy
    Mei-Rong Cui, Dan Zhang, Xian Peng Zheng, Huan Zhai, Mo Xie, Qin Fan, Lianhui Wang, Chunhai Fan, Jie Chao · 2024 · Journal of the American Chemical Society
88. Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
    Haixiang Pei, Yangrui Peng, Qiuhua Zhao, Yihua Chen · 2019 · RSC Advances
89. Protein Engineering in the Ubiquitin System: Tools for Discovery and Beyond
    Bo Zhao, Yien Che Tsai, Bo Jin, Bufan Wang, Yiyang Wang, Han Zhou, Tomaya Carpenter, Allan M. Weissman, Jun Yin · 2020 · Pharmacological Reviews
90. Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System
    Sascha Röth, Thomas Macartney, Agnieszka Konopacka, Kwok-Ho Chan, Houjiang Zhou, Markus A. Queisser, Gopal P. Sapkota · 2020 · Cell chemical biology
91. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
    Rui Li, Miao Liu, Zhenya Yang, Jiao Li, Yuxin Gao, Ruirong Tan · 2022 · Molecules
92. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs
    Adam Samuel Sperling, Michael W. Burgess, Hasmik Keshishian, Jessica A. Gasser, Shruti Bhatt, Max Jan, Mikolaj Michal Slabicki, Rob S. Sellar, Emma C. Fink, Peter Grant Miller et al. · 2019 · Blood
93. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation
    Zhang, Jing, Fu, Liqiang, Shen, Bin, Liu, Yingtao, Wang, Wenqian, Cai, Xin, Kong, Linglong, Yan, Yilin, Meng, Ryan, Zhang, Zhuming et al. · 2020 · Cell Chemical Biology
94. Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
    Zhangping Xiao, Shanshan Song, Deng Chen, Ronald van Merkerk, Petra E. van der Wouden, Robbert H. Cool, Wim J. Quax, Gerrit J. Poelarends, Barbro N. Melgert, Frank J. Dekker · 2021 · Angewandte Chemie International Edition
95. AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B
    Jia Xu, Xufen Yu, Tiphaine C. Martin, Ankita Bansal, Kakit Cheung, Abigail Lubin, Elias Stratikopoulos, Kaitlyn M. Cahuzac, Li Wang, Ling Xie et al. · 2021 · Cancer Discovery
96. Discovery of a Potent and Selective Degrader for USP7
    Yuan Pei, Jingfeng Fu, Yunkai Shi, Mengmeng Zhang, Guanghao Luo, Xiaomin Luo, Ning Song, Tian Mi, Yaxi Yang, Jia Xuan Li et al. · 2022 · Angewandte Chemie International Edition
97. Neuroprotective effects of targeting BET proteins for degradation with dBET1 in aged mice subjected to ischemic stroke
    Kelly M. DeMars, Changjun Yang, Eduardo Candelario‐Jalil · 2019 · Neurochemistry International
98. A patent review of BRD4 inhibitors (2013-2019)
    Tian Lu, Wenchao Lu, Cheng Luo · 2019 · Expert Opinion on Therapeutic Patents
99. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy
    Zonghui Ma, Ji Hoon Yu, Yifan Yu, Dailin Liang · 2021 · European Journal of Medicinal Chemistry
100. Selective targeting of non-centrosomal AURKA functions through use of a targeted protein degradation tool
     Richard Wang, Camilla Ascanelli, Ahmed Abdelbaki, Alex Fung, Tim Rasmusson, Iacovos N. Michaelides, Karen Roberts, Catherine Lindon · 2021 · Communications Biology